Camp4 Therapeutics is using regulatory RNA to target the genetic root causes of haploinsufficient diseases by modulating gene expression. The strategy now has c

Camp4 Therapeutics is using regulatory RNA to target the genetic root causes of haploinsufficient diseases by modulating gene expression. The strategy now has clinical traction, with Australian clearance for a Phase 1/2 trial of its SYNGAP1 therapy.